Orexin/Hypocretin receptor type 1 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Orexin/Hypocretin receptor type 1 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O43613. Start with insomnia, then reuse UniProt O43613 as the stable protein anchor across project notes and exports.
Start with insomnia, then reuse UniProt O43613 as the stable protein anchor across project notes and exports.
Orexin/Hypocretin receptor type 1 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.
Start review with insomnia because it currently carries approved-linked support. Linked drugs include DARIDOREXANT HYDROCHLORIDE, LEMBOREXANT, SB-649868. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyOrexin/Hypocretin receptor type 1
Review this target as Orexin/Hypocretin receptor type 1, mapped to UniProt O43613. Sequence length is 425 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Orexin/Hypocretin receptor type 1 as ChEMBL target CHEMBL5113, mapped to UniProt O43613. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Orexin/Hypocretin receptor type 1 is the right protein anchor across sources, using UniProt O43613 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why insomnia is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Orexin/Hypocretin receptor type 1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O43613 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Orexin/Hypocretin receptor type 1 |
| UniProt Accession | O43613 |
| Component Type | Protein |
| Sequence Length | 425 aa |
Orexin/Hypocretin receptor type 1
Review this target as Orexin/Hypocretin receptor type 1, mapped to UniProt O43613. Sequence length is 425 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Orexin/Hypocretin receptor type 1 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block.
Start review with insomnia because it currently carries approved-linked support. Linked drugs include DARIDOREXANT HYDROCHLORIDE, LEMBOREXANT, SB-649868. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3597953 | 10.22 | Ki | 0.06 | Preclinical |
| CHEMBL5079059 | 10.17 | EC50 | 0.068 | Preclinical |
| CHEMBL5619450 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL3906374 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL1830963 | 9.9 | Ki | 0.1259 | Preclinical |
| CHEMBL438925 | 9.89 | EC50 | 0.13 | Preclinical |
| CHEMBL1830961 | 9.8 | Ki | 0.1585 | Preclinical |
| CHEMBL3260826 | 9.7 | Ki | 0.2 | Preclinical |
| CHEMBL5618671 | 9.7 | IC50 | 0.2 | Preclinical |
| CHEMBL3981385 | 9.52 | IC50 | 0.3 | Preclinical |